Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 15/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289404 | 0.80 | NR3C2 (0.60) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4290850 | 0.77 | NR3C2 (0.50) | NR3C2NR3C1ARPGRPARP1 | |
| SCHEMBL4286505 | 0.73 | NR3C2 (0.45) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4290368 | 0.72 | NR3C2 (0.43) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4288454 | 0.72 | NR3C2 (0.43) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4290666 | 0.71 | NR3C2 (0.58) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4293819 | 0.68 | NR3C2 (0.60) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4290789 | 0.68 | NR3C2 (0.60) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL4288508 | 0.67 | NR3C2 (0.67) | NR3C2NR3C1ARPGRALDH1A1 | |
| SCHEMBL655255 | 0.66 | NR3C2 (0.47) | NR3C2NR3C1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | NR3C2 1/4885NR3C1 2/4885AR 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.